Preloader

Altera™ Whole Exome (WES) + Transcriptome (WTS)

Comprehensive Genomic Profiling

Altera™ combines Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) to enable deeper understanding of each cancer’s unique genomic signature. It identifies clinically relevant biomarkers that support the selection of targeted therapies and immunotherapies, while also helping match patients to appropriate clinical trials.

Technical Features

  • Whole Exome DNA Sequencing (WES)
    Analyzes approximately 20,000 genes to identify genomic alterations associated with targeted and immunotherapy options, including SNVs, indels, and CNAs. Also evaluates MSI and TMB status.
  • Whole Transcriptome RNA Sequencing (WTS)
    Extends analysis beyond the exome to detect structural rearrangements, clinically significant transcripts (such as AR-V7 and EGFR vIII), and fusions that may be missed by conventional panels (including NTRK 1/2/3).
  • IHC (Immunohistochemistry)
    Includes PD-L1 (22C3) and HER2 assessment to support personalized treatment strategy.

Technical Specifications

Feature

Details

Method

WES (DNA) + WTS (RNA) + IHC

Coverage

~20,000 Genes, MSI, TMB, PD-L1 (22C3), HER2, Fusions, and Drug Sensitivity

Sample Type

FFPE Tumor Tissue + EDTA Blood

Clinical Utility

Targeted therapy selection

Immunotherapy eligibility

Clinical trial matching

Turnaround Time

3 Weeks


While
Altera™ determines the optimal treatment strategy, Signatera enables molecular recurrence monitoring. This dual approach ensures tissue conservation by utilizing a single tumor sample. It optimizes the therapeutic process and provides the opportunity for long-term personalized monitoring.

//
Our customer support team is here to answer your questions!